We reviewed MR-guided high intensity focused ultrasound treatments (MRgFUS) of extra-abdominal desmoid tumors (DTs) in our institution from 02/2013 until 12/2020. The primary endpoints for assessing efficacy are post-treatment change in tumor volume, response based on RECIST and mRECIST; secondary endpoints are change in pain and quality of life. Complications are also reported. Our study demonstrates MRgFUS is an effective treatment option for first line and salvage therapy of desmoid tumors.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords